| Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. | None |
| Differences underlying EGFR and HER2 oncogene addiction. | None |
| Sequence-dependent oligomerization of the Neu transmembrane domain suggests inhibition of conformational switching by an oncogenic mutant. | None |
| rat Neu TM domain forms strong oligomers and the oncogenic mutation results in a reduced level of self-association. The proto-oncogenic Neu TM domain can adopt multiple (at least two) oligomeric conformations in the membrane. | None |
| Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways. | None |
| [Roles of proto-oncogene c-erbB2 during the initiation growth of rat primordial follicles]. | None |
| T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. | None |
| The tumor suppressor RECK interferes with HER-2/Neu dimerization and attenuates its oncogenic signaling. | None |
| Her-2/neu oncogene amplification determined by fluorescence in situ hybridization. | None |
| Rodent p53 suppresses the transforming activity of the activated Neu oncogene by modulating the Basal promoter activity of Neu. | None |
| When tumor suppressor TGFbeta meets the HER2 (ERBB2) oncogene. | None |
| Azatyrosine inhibits the activation of c-Raf-1, c-Jun and AP1 but not the activation of Ras during signal transduction triggered by oncogenic c-ErbB-2. | None |
| Suppressed autophosphorylation and tyrosine kinase-activity in revertant cell-lines expressing rat Neu oncogene. | None |
| c-erbB-2 oncoprotein expression in mammary and extramammary Paget s disease: an immunohistochemical study. | None |
| Data show that C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression. | None |
| Alterations of tumor suppressor genes such as CDKN2A and oncogenes such as ERBB2 play a role in the progression of intestinal metaplasia to adenocarcinoma in patients with Barrett_s esophagus. | None |
| Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett s esophagus with high-grade dysplasia or adenocarcinoma. | None |
| Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein. | None |
| Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. | None |
| [Expression of epidermal growth factor receptor and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin in rats]. | None |